Success Metrics

Clinical Success Rate
85.1%

Based on 57 completed trials

Completion Rate
85%(57/67)
Active Trials
5(6%)
Results Posted
35%(20 trials)
Terminated
10(12%)

Phase Distribution

Ph phase_4
11
13%
Ph phase_3
15
18%
Ph early_phase_1
6
7%
Ph not_applicable
6
7%
Ph phase_2
18
22%
Ph phase_1
23
28%

Phase Distribution

29

Early Stage

18

Mid Stage

26

Late Stage

Phase Distribution79 total trials
Early Phase 1First-in-human
6(7.6%)
Phase 1Safety & dosage
23(29.1%)
Phase 2Efficacy & side effects
18(22.8%)
Phase 3Large-scale testing
15(19.0%)
Phase 4Post-market surveillance
11(13.9%)
N/ANon-phased studies
6(7.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.8%

57 of 68 finished

Non-Completion Rate

16.2%

11 ended early

Currently Active

5

trials recruiting

Total Trials

83

all time

Status Distribution
Active(5)
Completed(57)
Terminated(11)
Other(10)

Detailed Status

Completed57
Terminated10
unknown10
Recruiting4
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
83
Active
5
Success Rate
85.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (7.6%)
Phase 123 (29.1%)
Phase 218 (22.8%)
Phase 315 (19.0%)
Phase 411 (13.9%)
N/A6 (7.6%)

Trials by Status

recruiting45%
terminated1012%
completed5769%
withdrawn11%
active_not_recruiting11%
unknown1012%

Recent Activity

Clinical Trials (83)

Showing 20 of 83 trialsScroll for more
NCT05838599Early Phase 1

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

Recruiting
NCT02600949Phase 1

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Recruiting
NCT03276832Early Phase 1

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Completed
NCT01795313Phase 1

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

Terminated
NCT03534947Phase 2

A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma

Completed
NCT02059499Phase 3

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

Completed
NCT03196180Early Phase 1

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

Completed
NCT06356012Phase 4

Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod

Recruiting
NCT02078648Phase 1

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Completed
NCT04809662

Comparing Immune Responses to Topical Imiquimod

Terminated
NCT02135419Phase 3

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Completed
NCT01803152Phase 1

Dendritic Cell Vaccine for Children and Adults With Sarcoma

Completed
NCT02394132Phase 3

Radiotherapy or Imiquimod in Complex Lentigo Maligna

Completed
NCT00799110Phase 2

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Active Not Recruiting
NCT02864147Phase 2

Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)

Completed
NCT05405270

Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment

Recruiting
NCT00788164Phase 1

Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

Completed
NCT00314756Phase 4

Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage

Completed
NCT05740969Phase 2

Gene and Protein Expression Profiles After Treatment of Actinic Keratoses

Unknown
NCT05468606Early Phase 1

Coadministration of GA2 Sporozoites With Adjuvants

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
83